Skip to search formSkip to main contentSkip to account menu

talazoparib

An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Talazoparib… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (1)

BMN 673
NCIt Antineoplastic Agent TerminologyPARP1 protein, human

Broader (2)

PhthalazinesPoly(ADP-ribose) Polymerase Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts
Background: Avelumab, a human IgG1 anti–PD-L1 monoclonal antibody, has shown antitumor activity and a manageable safety profile… 
2020
2020
TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA…
5566Background: PARP inhibitors (PARPi) show antitumor activity in mCRPC/DDRm pts treated with novel hormonal therapy (NHT… 
2020
2020
Talazoparib Exposure‐Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial
In the phase 3 EMBRACA trial, treatment with the poly(ADP‐ribose) polymerase inhibitor, talazoparib, led to significantly… 
2019
2019
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Abstract Background Talazoparib is a poly(adenosine diphosphate-ribose) polymerase inhibitor that causes death in cells with… 
Review
2019
Review
2019
JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer.
TPS9 Background: Preclinical studies suggest that chemotherapy (CTX) and PARP inhibitors may increase tumor antigenicity… 
2019
2019
A Phase 1 Mass Balance Study of 14C‐Labeled Talazoparib in Patients With Advanced Solid Tumors
This paper describes the pharmacokinetics (PK), mass balance, metabolic profiling, and safety of talazoparib after a single oral… 
Review
2018
Review
2018
The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
  • Ying ChenHui Du
  • Biomedicine & pharmacotherapy = Biomedecine…
  • 2018
  • Corpus ID: 48356688
2017
2017
A feasibility study of neoadjuvant talazoparib for early-stage breast cancer patients with a germline BRCA pathogenic variant: NCT02282345.
TPS595Background: Poly-(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a family of enzymes responsible for DNA repair… 
2017
2017
Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors.
10542Background: Poly (ADP-ribose) Polymerase inhibitors (PARPi) target tumors with deficiencies in DNA repair mechanisms… 
2015
2015
A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer…
TPS1107 Background: Poly-ADP-ribose polymerase (PARP) represents a family of enzymes of which at least two (PARP1 and PARP2) play… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)